From Cell Line To Clinic: 4 Months Sooner With mAb Accelerator

Early-stage bottlenecks frequently delay promising biologics, pushing timelines back before cell line development even begins. A specialized advancement framework eliminates these operational hurdles by launching cell line development immediately while organizational approvals and funding are finalized.

This parallel path provides a vital four-month head start, compressing the traditional timeline from gene to GMP drug substance down to nine months, and drug product to ten months. Powered by high-titer platforms delivering 7–12 g/L and global single-use capacity, the solution shares early technical and operational risks. Milestone-aligned commercial structures preserve capital runway during the highest-risk development phases, establishing a low-risk, rapid pathway to clinical entry.

Download the full brochure to explore the integrated timeline and accelerate your molecule's journey to the clinic.